share_log

Needham Reiterates Buy on Neumora Therapeutics, Maintains $5 Price Target

Benzinga ·  Mar 4 07:24

Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:NMRA) with a Buy and maintains $5 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment